First-in-Human Study of the Oral ALK Inhibitor Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Research To Practice
NCCP Protocol Summary for XXX Drug and XXX Disease
Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects - Xu - 2015 - The Journal of Clinical Pharmacology - Wiley Online Library
Crizotinib Ver 1
Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients | PLOS ONE
Crizotinib - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer | Future Oncology
Crizotinib Capsules
Crizotinib attenuates cancer metastasis by inhibiting TGFβ signaling in non-small cell lung cancer cells | Experimental & Molecular Medicine
Lucicriz-250 Lung Cancer Crizotinib Capsules, 250mg, Packaging Type: Bags,Box at Rs 75000/pack in Vadodara
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer - ScienceDirect
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study - The
Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models | Journal of Pharmacology and Experimental Therapeutics
Cancers | Free Full-Text | Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial
Grade ≥3 treatment-related adverse events classified by study phase,... | Download Scientific Diagram
Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients - Groenland - 2021 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Frontiers | Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro
Weiterbehandlung nach Krankheitprogress und Lebensqualität unter Crizotinib - 06 - 2015 - Heftarchiv - AMT
Xalkori Dosage/Direction for Use | MIMS Philippines
Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells - ScienceDirect
Crizotinib - wikidoc
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry
Serious adverse events requiring crizotinib dose modification | Download Table
XALKORI® (crizotinib) For ALK+ or ROS1+ mNSCLC Treatment | Safety Info
